Published in Journal of Wound Care | October 2023
A clinical study evaluating the spatially modulated Er:YAG laser combined with RecoSMA® technology for the treatment of diabetic ulcers was published in the October 2023 issue of the Journal of Wound Care (Vol 32, No 10, Silk Road Supplement).
The study, led by Dr. Ram M. Chilgar (India), assessed a two-step regenerative laser protocol in 59 patients with hard-to-heal diabetic ulcers.
Study Overview
Patients received weekly treatment consisting of:
The primary endpoint was complete wound closure.
Key Clinical Findings
Mechanistic Insight
The authors describe how Er:YAG laser ablation rapidly vaporises devitalised tissue while avoiding collateral thermal injury. RecoSMA® technology spatially modulates the laser beam into microbeams that create controlled mechanical resonance waves in deeper tissue layers.
This process:
Selected Quotes from the Publication
“Er-YAG lasers achieved wound closure in all 59 hard-to-heal diabetic ulcers with a mean of 4.41 treatments.”
“Debridement and biostimulation of the patients’ own inflammatory mechanism resulted in complete healing.”
“The treatment was convenient for the patients as it could be performed on an outpatient basis.”
“RecoSMA technology provided a convenient, cost-effective and efficient solution to diabetic ulcer healing.”
Clinical Implications
Diabetic foot ulcers remain a leading cause of lower limb amputation worldwide. The study suggests that Er:YAG laser combined with RecoSMA® may offer:
This publication contributes to the expanding clinical evidence supporting regenerative laser strategies in chronic wound management.
A clinical study evaluating the spatially modulated Er:YAG laser combined with RecoSMA® technology for the treatment of diabetic ulcers was published in the October 2023 issue of the Journal of Wound Care (Vol 32, No 10, Silk Road Supplement).
The study, led by Dr. Ram M. Chilgar (India), assessed a two-step regenerative laser protocol in 59 patients with hard-to-heal diabetic ulcers.
Study Overview
Patients received weekly treatment consisting of:
- High-power Er:YAG laser ablation to remove necrotic tissue and biofilm
- RecoSMA®-mediated spatial modulation to stimulate deep tissue regeneration
The primary endpoint was complete wound closure.
Key Clinical Findings
- 100% wound closure achieved in all 59 patients
- Mean number of sessions required: 4.41
- Average initial wound area: 25 cm²
- No recurrence observed during long-term follow-up (average 22.95 months)
Mechanistic Insight
The authors describe how Er:YAG laser ablation rapidly vaporises devitalised tissue while avoiding collateral thermal injury. RecoSMA® technology spatially modulates the laser beam into microbeams that create controlled mechanical resonance waves in deeper tissue layers.
This process:
- Retriggers the inflammatory phase
- Stimulates fibroblast proliferation
- Promotes collagen and extracellular matrix formation
- Enhances neoangiogenesis
Selected Quotes from the Publication
“Er-YAG lasers achieved wound closure in all 59 hard-to-heal diabetic ulcers with a mean of 4.41 treatments.”
“Debridement and biostimulation of the patients’ own inflammatory mechanism resulted in complete healing.”
“The treatment was convenient for the patients as it could be performed on an outpatient basis.”
“RecoSMA technology provided a convenient, cost-effective and efficient solution to diabetic ulcer healing.”
Clinical Implications
Diabetic foot ulcers remain a leading cause of lower limb amputation worldwide. The study suggests that Er:YAG laser combined with RecoSMA® may offer:
- Effective outpatient treatment
- Reduced need for surgical reconstruction
- Accelerated healing through regenerative stimulation
- A non-thermal, biologically controlled intervention
This publication contributes to the expanding clinical evidence supporting regenerative laser strategies in chronic wound management.
